Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis

Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis

Currently chondroitin sulfate (CS) is the most studied drug from the group of «chondroprotectors». The article shows the role of CS in the treatment of osteoarthritis (OA): mechanism of action, clinical efficacy and safety in patients with OA with comorbidity. Evidence for the effectiveness and safe...

Full description

Bibliographic Details
Main Authors:	E. P. Sharapova, E. A. Taskina, N. G. Kashevarova, L. I. Alekseeva, A. M. Lila
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2021-08-01
Series:	Современная ревматология
Subjects:	остеоартрит коленных, тазобедренных суставов хондроитина сульфат хондрогард<sup>®</sup> эффективность безопасность нежелательные явления
Online Access:	https://mrj.ima-press.net/mrj/article/view/1181

Similar Items

Comparative study of the efficacy and safety of Chondroguard® during its combined (intra-articular and intramuscular) and intramuscular injection in patients with knee osteoarthritis
by: L. I. Alekseeva, et al.
Published: (2018-06-01)

Etoricoxib for generalized osteoarthritis. Case report
by: I. S. Dydykina, et al.
Published: (2021-02-01)

Current possibilities of pharmacological correction of neuroimmune joint damage in patients with knee osteoarthritis in long COVID conditions
by: I. V. Sarvilina, et al.
Published: (2022-06-01)

The use of injectable chondroitin sulfate in combination with dosed physical exercise for the treatment of patients with hand osteoarthritis
by: L. V. Vasilyeva, et al.
Published: (2020-09-01)

Efficacy and safety of diacerein in patients with knee osteoarthritis
by: L. I. Alekseeva, et al.
Published: (2017-09-01)

Standardised Forms of Chondroitin Sulfate as a Pathogenetic Treatment of Osteoarthritis in the Context of Post-Genomic Studies
by: O. A. Gromova, et al.
Published: (2021-02-01)

Chondroitin sulfate: the mechanisms of action, its efficacy and safety in the therapy of osteoarthrosis
by: S G Anikin, et al.
Published: (2012-09-01)

Step-by-step therapy with chondroitin sulfate in patients with osteoarthritis in an outpatient setting
by: L. V. Vasilyeva, et al.
Published: (2017-09-01)

Russian experience with injectable chondroitin sulfate and glucosamine sulfate: a review of clinical trials
by: A. E. Karateev, et al.
Published: (2018-04-01)

Synovitis in osteoarthritis: the current state of the problem
by: I. S. Dydykina, et al.
Published: (2021-04-01)

Hand osteoarthritis: pathogenesis, diagnosis, and approaches to therapy
by: N. A. Shostak, et al.
Published: (2019-10-01)

Evaluation of the efficacy of injectable chondroitin sulfate for knee osteoarthritis in real clinical practice
by: E. Yu. Pogozheva, et al.
Published: (2019-09-01)

Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis
by: A. P. Rebrov, et al.
Published: (2016-06-01)

The efficacy and safety of glycosaminoglycan-peptide complex in patients with knee osteoarthritis and comorbidity: a multicenter prospective study
by: L. I. Alekseeva, et al.
Published: (2021-02-01)

Morphological reflection of highly purified chondroitin sulfate action in patients with decompensated form of knee osteoarthritis
by: T. B. Minasov, et al.
Published: (2022-12-01)

The efficacy and tolerability of the slow-acting combined agent glucosamine and chondroitin sulfate in gonarthrosis patients tacking no nonsteroidal anti-inflammatory drugs
by: A. P. Rebrov, et al.
Published: (2016-01-01)

Important aspects of osteoarthritis therapy during the COVID-19 pandemic
by: A. M. Lila, et al.
Published: (2022-02-01)

Evaluation of the efficacy and safety of a combination of chondroitin sulfate and glucosamine sulfate for knee and hip osteoarthritis in real clinical practice
by: A. E. Karateev, et al.
Published: (2020-11-01)

Treatment of knee joint osteoarthritis in overweight women in outpatient practice
by: P. S. Kovalenko, et al.
Published: (2021-08-01)

The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study
by: A. M. Lila, et al.
Published: (2020-09-01)

DIAGNOSTIC EFFECTIVENESS OF A NEW METHOD FOR COMPREHENSIVE ASSESSMENT OF THE DEGREE OF HIP DYSPLASIA IN CHILDREN
by: V. V. Zotkin, et al.
Published: (2020-11-01)

Contribution of neurogenic mechanisms to the pathogenesis of chronic joint pain
by: E. S. Filatova, et al.
Published: (2021-04-01)

Pharmacoinformation studies of chondroprotectors
by: A. M. Lila, et al.
Published: (2021-10-01)

Symptom-modifying slow-acting drugs in the treatment of osteoarthritis: from molecule to clinical effect (a pharmacologist's view)
by: A. S. Dukhanin
Published: (2018-06-01)

Evidence-based therapy for knee osteoarthritis: expected short-, medium-, and long-term outcomes of prescription crystalline glucosamine sulfate administration
by: L. N. Denisov, et al.
Published: (2022-08-01)

Advantages of osteoarthritis combined treatment with symptomatic slow-acting drugs
by: E. V. Zonova
Published: (2021-04-01)

The use of new aceclofenac dosage forms in patients with osteoarthrosis in real-life clinical practice
by: Lyudmila Ivanovna Alekseeva, et al.
Published: (2014-03-01)

RATIONAL THERAPY OF OSTEOARTHRITIS IN OUTPATIENT CONDITIONS
by: E. E. Savelova, et al.
Published: (2014-07-01)

RATIONAL THERAPY OF OSTEOARTHRITIS IN OUTPATIENT CONDITIONS
by: E. E. Savelova, et al.
Published: (2014-07-01)

Biologically active additives in the 21st century: undenatured type II collagen as an example of good medical practice
by: I. S. Dydykina, et al.
Published: (2020-05-01)

Osteoarthritis: Key elements in its pathogenesis and current agents for pathogenetic therapy
by: Yu. A. Olyunin, et al.
Published: (2017-09-01)

THE CORES A SYMPTOM-MODIFYING PREPARATIONS OF THE SLOWEDDOWN ACTION IN THERAPY OF OSTEOARTROSIS
by: V V Badokin, et al.
Published: (2010-04-01)

FAKTORY PROGRESSIROVANIYa OSTEOARTROZA KOLENNYKh SUSTAVOV (5-letnee prospektivnoeNABLYuDENIE)
by: N G KAShEVAROVA, et al.
Published: (2013-12-01)

A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 2: Evaluation of the efficacy of the drug in different use regimens
by: E. P. Sharapova, et al.
Published: (2020-03-01)

DEVELOPMENT OF METHOD FOR DETERMINATION OF INTRINSIC VISCOSITY OF INJECTABLE DRUG WITH CHONDROITIN SULFATE
by: K. R. Saveleva, et al.
Published: (2019-01-01)

Применение иАПФ при бронхообструктивных заболеваниях: безопасность и нежелательные лекарственные реакции
Published: (2018-06-01)

Basic symptom-modifying delayed-action drugs in therapy of osteoporosis
by: Vladimir Vasil'evich Badokin, et al.
Published: (2011-09-01)

Osteoarthritis of hand joints: prevalence, risk factors, phenotypes, diagnosis, treatment
by: L. I Alekseeva, et al.
Published: (2022-12-01)

On the prospects for the use of undenatured type II collagen in the treatment of osteoarthritis and other joint diseases
by: O. A. Gromova, et al.
Published: (2022-08-01)

The relationship and interinfluence of aspects of therapy safety and compliance in patients with cardiovascular diseases (by the data from outpatient registry “PROFILE”)
by: Yu. V. Lukina, et al.
Published: (2018-10-01)